I don't understand? It would be far more costly to obtain insulin from rats and turn it into a powder than to sell recombinant IGF-1. This smells like a rat alright, the rat being a competitor??????
They also use BSA in human meds!!!!
Research paper
IgG antibodies against bovine serum albumin in humans—their prevalence and response to exposure to bovine serum albumin
Tirsit Mogues, Junzhi Li, John Coburn and David J. KuterCorresponding Author Contact Information, E-mail The Corresponding Author
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Received 8 January 2005;
accepted 15 January 2005.
Available online 18 April 2005.
Purchase the full-text article
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
Human exposure to bovine serum albumin (BSA) is very common and occurs through dietary and medicinal routes. Although great effort has been made to reduce exposure to BSA in pharmaceuticals to eliminate the threat of bovine spongiform encephalopathy, less attention has been given to assessing the human immune response after exposure to BSA. A sensitive quantitative radioimmunoassay was therefore developed to measure anti-BSA IgG antibodies in healthy subjects and in cancer patients participating in a randomized, placebo controlled clinical trial where they were exposed to BSA as an intrathoracic surgical sealant during pneumonectomy. Anti-BSA antibodies were detected in 55% of 60 healthy blood donors and 51% of 83 patients before lung cancer resection. The median antibody levels were the same in both cohorts; 0.086 μg/mL (range 0.016–19.5 μg/mL) for health blood donors and 0.062 μg/mL (range 0.009–44 μg/mL) for cancer patients. Six months after exposure of the cancer patients to BSA, the percentage of patients with anti-BSA antibody rose to 96% and the median antibody level rose to 19 μg/mL (range 0.009–258 μg/mL). Placebo-treated cancer patients showed no significant increase in the percentage of patients with anti-BSA antibody (41%) or the median antibody level (0.047 μg/mL; range 0.008–1.58) over 6 months. Western blot analysis confirmed the presence of anti-BSA antibody. Elevated levels of anti-BSA antibody were not associated with any detectable clinical events in either the healthy blood donors or the cancer patients.
Keywords: Antibody; Bovine serum albumin; BSA; Human immune response; Radioimmunoassay
Abbreviations: BSA, bovine serum albumin; BSE, bovine spongiform encephalopathy; PBS, phosphate-buffered saline; ECL, enhanced chemiluminescence; HSA, human serum albumin; LOD, limit of detection; LOQ, limit of quantitation
